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AED, antiepileptic drug; ETH, ethosuximide; GBP, gabapentin; VGB, vigabatrin; LEV, 
levetiracetam;  NaVP,  sodium  valproate;  PTZ,  pentylenetetrazole;  TEA, 
tetraethylammonium chloride; PILO, pilocarpine hydrochloride; NF, normal food; GO, 
gene ontology; FDR, false discovery rate; SAM, significant analysis of microarrays.
Abstract
A  Drosophila behavioral and transcriptomic model of locomotor plasticity induced by 
chronic pentylenetetrazole (PTZ) has recently been developed. In this model, two of the 
five  antiepileptic  drugs  (AEDs)  tested,  sodium  valproate  (NaVP)  and  levetiracetam 
(LEV), not ethosuximide (ETH), gabapentin (GBP) and vigabatrin  (VGB), ameliorate 
development of chronic PTZ induced locomotor alteration. Transcriptomic effect of the 
AEDs and PTZ in fly head has been described. Here, we analyze microarray expression 
profile of heads of flies treated with the convulsants tetraethylammonium chloride (TEA) 
and pilocarpine hydrochloride (PILO). Strikingly, microarray clustering placed TEA, not 
PILO, with LEV and NaVP in one group that was distinct from the other one consisting 
of  PTZ,  GBP,  VGB and  ETH.  Further,  like  LEV  and  NaVP,  TEA  regulated  genes 
overrepresented ribosomal and energy metabolic pathways. Also, TEA, like LEV and 
NaVP, ameliorated development of locomotor deficit in the chronic PTZ model. Both 
transcriptomic  and  behavioral  analyses  thus  demonstrated  LEV-  and  NaVP-  like 
neuroprotective  effect  of  TEA.  Our  results  are  consistent  with  earlier  paradoxical 
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evidence suggesting that TEA may be neuroprotective. Amenability of Drosophila model 
thus provides an excellent opportunity to understand long term mechanisms of action of 
centrally acting drugs in molecular details.
Keywords
Tetraethylammonium,  pilocarpine,  transcriptomic,  behavioral,  Drosophila model, 
neuroprotective
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Introduction
The chemoconvulsant PTZ is used to model epileptogenesis and test AEDs in rodents (de 
Oliveira  et  al.,  2008).  Recently,  a  novel  Drosophila systems  model  of  PTZ induced 
locomotor plasticity responsive to antiepileptic drugs has been developed (Mohammad et 
al., 2009). In this model, seven days of PTZ treatment and seven days of subsequent PTZ 
discontinuation  respectively  cause  a  decreased  and  an  increased  climbing  speed  in 
Drosophila adults.  Concomitant  treatment  shows that  two of  the  five  AEDs tested  - 
NaVP and LEV, not ETH, GBP and VGB – are able to suppress the development of 
locomotor deficit at the end of chronic PTZ phase. Microarray expression profiling of 
heads  of  flies  treated  with  PTZ  has  shown  that  the  drug  induces  down-,  not  up-, 
regulation of genes (Mohammad et al., 2009). These genes show enrichment of various 
gene ontology (GO) biological processes such as transcription,  neuron morphogenesis 
during  differentiation,  synaptic  transmission,  regulation  of  neurotransmitter  levels, 
neurogenesis, axonogenesis, axon guidance, glutamate metabolism etc. (Mohammad et 
al.,  2009).  Notably,  the  Drosophila gene  expression  model  has  been  found  to  be 
consistent with transcriptomic and proteomic data pertaining to established rodent models 
of epilepsy and human epileptic patients (Mohammad et al., 2009).
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Besides epilepsy, AEDs are also used in treating various neurological and psychiatric 
conditions ([Rogawski and Loscher,  2004], [Johannessen,  2008] and [Grunze,  2008]). 
Epilepsy and these other  nonepileptic  conditions are  considered  to  share  overlapping 
pathophysiological  mechanisms  ([Rogawski  and  Loscher,  2004]  and  [Adams et  al., 
2008]). Whereas the immediate biochemical effects of AEDs are known to some extent, 
the  mechanisms  of  longer-term  therapeutic  action  of  these  drugs  are  unclear 
([Johannessen, 2008], [Rosenberg, 2007], [Nagarkatti et al., 2008] and [Kuzniecky et al., 
2008]).  Given this, availability of the fly model showing LEV and NaVP as effective and 
ETH,  GBP and VGB as  ineffective  drugs  offers  a  unique  opportunity  to  understand 
mechanisms of long term action of AEDs at systems level. The effect of the above AEDs 
on fly head transcriptome has provided evidence that ribosomal and energy metabolic 
pathways are  involved in  their  mechanisms of action (Singh et  al.,  manuscript  under 
review). It has been hypothesized that drugs’ neurometabolic effects lead to alteration in 
epigenetic  codes  in  the  brain  via  regulation  of  ribosomal  proteins  (Singh  et  al., 
manuscript under review).
Given the demonstrated usefulness of the fly model in unraveling long term mechanisms 
of centrally acting drugs, we considered it important to characterize it further. For this, 
we generated microarray expression profiles of fly heads obtained from animals treated 
with the convulsant agents TEA and PILO in a chronic manner.  Strikingly, we found 
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transcriptomic effect of TEA as similar to that of LEV and NaVP. Like LEV and NaVP, 
TEA also ameliorated development of locomotor deficit caused by chronic PTZ in the fly 
model. The results obtained using both transcriptomic and behavioral modules of the fly 
model are presented.
Materials and methods
Drug treatment and locomotor analysis
Unless  mentioned  otherwise,  previously  described  materials  and  methods  were  used 
(Mohammad et  al.,  2009).  Standard  methods  of  fly  handling  and manipulation  were 
followed. Final concentration of PTZ, TEA and PILO (all from Sigma-Aldrich) in the fly 
medium was 8, 16 and 1.5 mg/ml, respectively. These concentrations were based on LC50 
analysis. LC50,  defined as concentration in normal fly media causing 50% lethality in 
seven days, was previously determined for PTZ and AEDs [2]. We similarly determined 
LC50  for TEA and PILO. Half of LC50 was used for drug treatment described here. At 
these  concentrations,  lethality  was reduced to  less  than 10%. Three  to  four  days  old 
unmated  D. melanogaster adult males were used for drug treatment. Flies treated with 
normal food (NF) served as controls. The effectiveness of TEA in PTZ locomotor model 
was tested using a modified version of the screen. In this version,  flies were treated in 
parallel in three vials sequentially; 12 hrs in one, three and a half days in another, and 
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three days in still another vial. A set of (i) control flies were treated with NF in all three 
vials, (ii) PTZ flies were treated with PTZ in first vial and with NF in second and third 
vials, (iii) TEA flies were treated with TEA in first and second vials and with NF in two 
subsequent vials, and (iv) PTZ+TEA flies were treated with both PTZ and TEA together 
in first vial, with TEA alone in second vial, and with NF in third vial.  Climbing speed 
was measured as previously described (Mohammad et al., 2009).
Microarray analysis
For microarray analysis, three to four days old unmated males were used to begin seven 
day long TEA or  PILO treatment.  Previously described microarray  method was used 
(Mohammad et al., 2009). In brief, total RNA was isolated from frozen fly heads using 
TRI REAGENT (Sigma), according to the manufacturer’s protocol. Microarray -cDNA 
Synthesis  Kit,  -Target  Purification Kit,  and -RNA Target  Synthesis Kit (Roche) were 
used to generate labeled antisense RNA. Four biological replicates, with balanced dye-
swap,  were  used  for  generating  expression  profiles.  The  hybridization  mixture  was 
denatured at 65ºC and applied onto cDNA microarray slides (12Kv1, CDMC, Canada). 
Analyzable spots in at least three of four biological replicates performed were retrieved 
for downstream analysis using Significant Analysis of Microarray (SAM 3, Excel Add-
In), under the conditions of one class response and 100 permutations. Wherever absent in 
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the fourth replicate, the values were imputed using SAM. All microarray data reported in 
the manuscript is described in accordance with MIAME guidelines. The full microarray 
data  set  has  been  deposited  in  the  Gene  Expression  Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) under accession series GSE7783 and GSE7787. For 
cluster analysis, all four values in the entire set were used. The cluster was generated 
using Acuity 4.0 (Molecular Devices). Previously described microarray data related to fly 
treatment  of PTZ, GBP, VGB, ETH, LEV and NaVP ([Mohammad et al.,  2009] and 
[Singh et al., manuscript under review]) was used for clustering with newly generated 
TEA or PILO profiles. Differentially expressed genes were identified at an average false 
discovery rate (FDR) of 20% (range 18-22%). Earlier, a control microarray experiment 
compared heads of different batches of flies treated with NF using the same procedure 
used here (Mohammad et al., 2009). No differentially expressed gene was found in this 
NF versus NF microarrays in SAM analysis up to 96% FDR. Given this, our selection of 
FDR in the present analysis was based on a compromise between uniformity across time 
points in terms of number of differentially expressed genes and acceptability in terms of 
incorporating false positives.  Gene symbols or  IDs of fly genes were  retrieved using 
FLIGHT (http://www.flight.licr.org/). Gene ontology (GO) biological process and KEGG 
pathway  enrichment  were  analyzed  (http://david.abcc.ncifcrf.gov/home.jsp)  using 
DAVID  (Dennis  et  al.,  2003).  KEGG 
(http://www.genome.jp/kegg/tool/color_pathway.html)  was used for  depicting genes in 
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the pathways.
Results
TEA behaves like LEV and NaVP in the transcriptomic module
We  first  generated  microarray  gene  expression  profile 
(http://www.ncbi.nlm.nih.gov/geo/, GSE7783) of fly head after treating the flies with the 
epileptogenic  agent  TEA  for  7  d.  The  TEA  profile  was  clustered  with  previously 
described profiles  of the convulsant  PTZ and the AEDs GBP, VGB, ETH, LEV and 
NaVP  ([Mohammad  et  al.,  2009]  and  [Singh  et  al.,  manuscript  under  review]). 
Unexpectedly, the TEA profile showed similarity with LEV and NaVP profiles (Fig. 1A). 
We next generated expression profile  of fly head after  treating the flies with another 
convulsant  PILO  for  7  d  (http://www.ncbi.nlm.nih.gov/geo/,  GSE7787),  to  examine 
specificity of our analysis. Unlike TEA, PILO profile clustered with PTZ, GBP, VGB 
and ETH (Fig. 1B). This demonstrated that transcriptomic effect of TEA is indeed similar 
to  that  of  LEV  and  NaVP.  We  henceforth  focused  on  TEA  induced  transcriptomic 
alteration.
Downstream analysis of TEA profile identified 1022 upregulated and 36 downregulated 
genes (Supplementary Table S1). The upregulated genes showed overrepresentation of 
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several biological processes (Table 1). Previously, genes upregulated by LEV and NaVP 
were found to enrich ribosomal and energy metabolic pathways (Singh et al., manuscript 
under review). Notably, the enriched processes in TEA upregulated gene set (Table 1) 
included translation and carbohydrate metabolism. Pathway enrichment analysis of TEA 
gene set indeed showed significant enrichment of ribosomal pathway even when p value 
was adjusted for multiple testing (Table 2). Position of TEA genes in ribosomal pathway 
is shown in Fig. 2A. Correcting for multiple statistical testing may be overly conservative 
to  the  point  of  being  counterproductive  in  interpreting  microarrays  with  biological 
knowledgebases  (Osier  et  al.  2004).  Given  this,  and  considering  enrichment  of 
carbohydrate  metabolism  related  processes  (Table  1),  it  was  notable  that  TEA 
upregulated  genes  enriched  glycolysis/gluconeogenesis  at  nominal  p value  (Table  2). 
Position  of  TEA genes  in  glycolysis/gluconeogenesis  pathway  is  shown in  Fig.  2B. 
Cumulatively,  genes  upregulated  by  TEA,  like  LEV  and  NaVP,  were  found  to 
overrepresent ribosomal and energy metabolic pathways. TEA thus behaved like LEV 
and NaVP in the transcriptomic module of the fly model.
TEA tests positive in the behavioral module
Chronic treatment with PTZ alone is reported to cause development of reduced climbing 
speed on 7 d, whereas concomitant treatment with LEV or NaVP rescues the PTZ effect 
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(Mohammad et al., 2009). We next examined if TEA also ameliorates development of 
climbing abnormality  caused by chronic  PTZ.  Interestingly,  concomitant  treatment  of 
flies with PTZ and TEA together indeed caused no climbing deficit on 7 d. Climbing 
speed in  the drug  combination group was not  found to  be different  from that  in  NF 
control (Fig. 3). In contrast, flies in PTZ alone group, as expected, showed a decreased 
climbing speed. TEA itself also caused climbing abnormality.  Its own effect however 
could not have confounded PTZ and TEA combination treatment  result  because TEA 
alone,  like  PTZ  alone,  caused  a  decrease  in  speed.  Cumulatively,  TEA  showed 
effectiveness like LEV and NaVP in the behavioral module of the fly model.
Discussion
The Drosophila systems model predicts that the K+ channel blocker TEA may act like an 
AED. This may seem paradoxical because TEA, a pharmacological tool compound with 
decades of use in neuroscience research ([Tasaki and Hagiwar,  1957] and [Liu et al., 
2007]) is a known epileptogenic and convulsant agent. It is however interesting to note 
here that a  careful interpretation of an electrophysiological observation has once raised 
the suspicion that TEA may suppress epileptiform activity (Madeja et al., 2003). Further, 
evidence  exists  to  support  that  decreases  as  well  as  increases  of  neuronal  activity, 
resulting from increase or decrease of the K+ currents, for example, may suppress the 
11
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
41
8.
1 
: P
os
te
d 
10
 J
ul
 2
00
9
ability  of  the  neurons  to  produce  epileptic  discharges  (Speckmann and Elger,  1984). 
Furthermore, both increases as well as decreases of K+ currents have been described for a 
variety of AEDs. For example, antiepileptic effect of NaVP and LEV has been suggested 
to be due to their depressing effect on the K+ currents ([VanDongen et al., 1986], [Nobile 
and Vercellino, 1997] and [Madeja et al., 2003]). Our results showing similarity among 
LEV, NaVP and TEA in terms of their transcriptomic and behavioral effect in the fly 
model may possibly reflect their K+ current effects. Electrophysiological analysis will be 
required to understand K+ current effects of LEV, NaVP and TEA in the fly model. 
Experimental evidence in mammalian system suggests that K+ channel blockers such as 
TEA may be neuroprotective against pathologic neuronal death and apoptosis (Wei et al, 
2003, Wei et al, 2004, Ghoumari et al, 2006). Similarly, LEV and NaVP are considered 
to provide neuroprotection against cell death and apoptosis in the CNS (Cardile et al. 
2003, Kanai et al. 2004, Plant et al, 2009). Characterization of the fly model at cellular 
level will be required to examine apoptosis hypothesis of drugs’ therapeutic action. At 
this time, results obtained using the newly developed model allows to broadly conclude 
that long term effect of K+  channel blockers  may be of therapeutic  potential  in CNS 
disorders.  The Drosophila model has earlier provided evidence that LEV and NaVP act 
through upregulating ribosomal and energy metabolic pathways (Singh et al., manuscript 
under review). It has been speculated that neurometabolic effect of drugs lead to altered 
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epigenetic  codes  in  the  brain  via  regulation  of  ribosomal  proteins  (Singh  et  al., 
manuscript under review). Our present results support a similar mechanism for TEA.
Acknowledgements
The research was supported by NWP0034 grant of Council of Scientific and Industrial 
Research (CSIR), Government of India, to A.S. Junior and Senior Research Fellowships 
to M.F. and P.S. from CSIR is duly acknowledged.
Author’s contributions
The research was conceived and planned by A.S. The experiments were performed and 
the data collected by P.S. and F.M. All authors analyzed the data. A.S. interpreted the 
data and wrote the manuscript.
References
1. Adams, S.J., O’Brien, T.J., Lloyd, J., Kilpatrick, C.J., Salzberg, M.R., Velakoulis, D., 
2008. Neuropsychiatric morbidity in focal epilepsy. Br. J. Psychiatry 192, 464-469.
2. Cardile,  V.,  Pavone,  A.,  Gulino,  R.,  Renis,  M.,  Scifo,  C.,  Perciavalle,  V.,  2003. 
Expression of brain-derived neurotrophic factor (BDNF) and inducible nitric oxide 
13
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
41
8.
1 
: P
os
te
d 
10
 J
ul
 2
00
9
synthase (iNOS) in rat astrocyte cultures treated with Levetiracetam. Brain Res. 976, 
227-233.
3. de Oliveira,  P.A.,  Lino,  F.L.,  Cappelari,  S.E.,  da Silva  Brum,  L.F.,  Picada,  J.N., 
Patrícia Pereira,  P.,  2008. Effects of gamma-decanolactone on seizures induced by 
PTZ-kindling in mice. Exp. Brain Res. 187, 161-166.
4. Dennis,  G.Jr.,  Sherman,  B.T.,  Hosack,  D.A.,  Yang,  J.,  Gao,  W.,  Lane,  H.C., 
Lempicki,  R.A.,  2003.  DAVID:  Database  for  Annotation,  Visualization,  and 
Integrated Discovery. Genome Biol. 4, 3.
5. Ghoumari, A.M., Piochon, C., Tomkiewicz, C., Eychenne, B., Levenes, C., Dusart, I., 
Schumacher, M., Baulieu, E.E., 2006. Neuroprotective effect of mifepristone involves 
neuron depolarization. FASEB J. 20, 1377-1386.
6. Grunze,  H.C.,  2008. The effectiveness of  anticonvulsants  in  psychiatric  disorders. 
Dialogues Clin. Neurosci. 10, 77-89.
7. Johannessen,  L.C.,  2008.  Antiepileptic  drugs  in  non-epileptic  disorders:  relations 
between mechanisms of action and clinical efficacy, CNS Drugs 22, 27-47.
8. Kanai,  H.,  Sawa,  A.,  Chen,  R.W.,  Leeds,  P.,  Chuang,  D.M.,  2004.  Valproic  acid 
inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH 
nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J. 4, 336-
344.
14
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
41
8.
1 
: P
os
te
d 
10
 J
ul
 2
00
9
9. Kuzniecky,  R.,  Pan,  J.,  Burns,  A.,  Devinsky,  O.,  Hetherington,  H.,  2008. 
Levetiracetam  has  no  acute  effects  on  brain  gamma-aminobutyric  acid  levels. 
Epilepsy Behav. 12, 242-244.
10. Liu, H., Gao, Z.B., Yao, Z., Zheng, S., Li, Y., Zhu, W., Tan, X., Luo, X., Shen, J., 
Chen, K., Hu, G.Y., Jiang H., 2007.  Discovering potassium channel blockers from 
synthetic  compound  database  by  using  structure-based  virtual  screening  in 
conjunction with electrophysiological assay. J. Med. Chem. 50, 83-93.
11. Madeja,  M.,  Margineanu,  D.G.,  Gorji,  A.,  Siep,  E.,  Boerrigter,  P.,  Klitgaard,  H., 
Speckmann,  E.J.,  2003.  Reduction  of  voltage-operated  potassium  currents  by 
levetiracetam:  a novel antiepileptic mechanism of action? Neuropharmacology 45, 
661-671.
12. Mohammad,  F.,  Singh,  P.,  Sharma,  A.,  2009.  A  Drosophila  systems  model  of 
pentylenetetrazole  induced  locomotor  plasticity  responsive  to  antiepileptic  drugs. 
BMC Syst. Biol. 3, 11.
13. Nagarkatti, N., Deshpande, L.S., DeLorenzo, R.J., 2008. Levetiracetam inhibits both 
ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal 
neurons in culture. Neurosci. Lett. 436, 289-293.
14. Nobile,  M.,  Vercellino,  P.,  2004.  Inhibition  of  delayed  rectifier  K+ channels  by 
phenytoin in rat neuroblastoma cells. Br. J. Pharmacol. 120 (1997), pp. 647–652.
15
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
41
8.
1 
: P
os
te
d 
10
 J
ul
 2
00
9
15. M.V.  Osier,  H.  Zhao,  K.H.  Cheung,  Handling  multiple  testing  while  interpreting 
microarrays with the Gene Ontology Database. BMC Bioinformatics 5, 124.
16. Plant, K.E., Anderson, E., Simecek, N., Brown, R., Forster, S., Spinks, J., Toms, N., 
Gibson,  G.G.,  Lyon,  J.,  Plant,  N.,  2009.  The neuroprotective  action  of  the mood 
stabilizing drugs lithium chloride and sodium valproate is mediated through the up-
regulation of the homeodomain protein Six1. Toxicol. Appl. Pharmacol.  235, 124-
134.
17. Rogawski, M.A., Loscher, W., 2004. The neurobiology of antiepileptic drugs for the 
treatment of nonepileptic conditions. Nat. Med. 10, 685-692.
18. Rosenberg,  G.,  2007.  The mechanisms of  action  of  valproate  in  neuropsychiatric 
disorders: can we see the forest for the trees? Cell. Mol. Life Sci. 64, 2090-2103.
19. Speckmann, E-J, Elger, C.E., 1984. The neurophysiological basis of epileptic activity: 
a condensed overview. In: Degan, R., Niedermeyer, E. (Eds.),  Epilepsy, Sleep and 
Sleep Deprivation. Elsevier Science Publisher, Amsterdam, pp. 23–34.
20. Tasaki, I., Hagiwar, A.S., 1957.  Demonstration of two stable potential states in the 
squid giant axon under tetraethylammonium chloride. J. Gen. Physiol. 40, 859-885.
21. VanDongen,  A.M.J.,  VanErp,  M.G.,  Voskuyl,  R.A.,  1986.  Valproate  reduces 
excitability by blockage of sodium and potassium conductance.  Epilepsia 27, 177–
182.
16
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
41
8.
1 
: P
os
te
d 
10
 J
ul
 2
00
9
22. Wei, L., Yu, S.P., Gottron, F., Snider, B.J., Zipfel, G.J., Choi, D.W., 2003. Potassium 
channel blockers attenuate hypoxia- and ischemia-induced neuronal death in vitro and 
in vivo. Stroke 34, 1281-1286.
23. Wei, L., Xiao, A.Y., Jin, C., Yang, A., Lu, Z.Y., Yu, S.P., 2004. Effects of chloride 
and potassium channel blockers on apoptotic cell shrinkage and apoptosis in cortical 
neurons. Pflugers Arch. 448, 325-334.
17
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
41
8.
1 
: P
os
te
d 
10
 J
ul
 2
00
9
Figure legends
Figure 1.
Hierarchical clustering of microarray gene expression profiles. TEA (A) or PILO (B) 
profile  was  clustered  with  previously  described  profiles  associated  with  2  d  PTZ 
(Mohammad et al., 2009) and 7 d AED (Singh et al., 2009) treatment. Note clustering of 
TEA  with  LEV  and  NaVP,  and  of  PILO  with  PTZ,  ETH,  GBP  and  VGB.  Simple 
matching similarity metric  and average linkage method was used for clustering.  Each 
profile represents mean of normalized log2 ratio (635/532) of four biological replicates 
with balanced dye-swaps. The cluster was generated using Acuity 4.0.
Figure 2.
Overrepresentation  of  pathways  in  TEA  regulated  genes. Upregulated  genes  are 
indicated  as  red  boxes  in  the  KEGG  pathway 
(http://www.genome.jp/kegg/tool/color_pathway.html)  for  ribosome  (A)  and 
glycolysis/gluconeogenesis (B). Grey boxes represent other pathway components present 
in Drosophila melanogaster.
Figure 3.
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Effect of TEA on development of PTZ induced locomotor deficit. Mean ± S. E. (n = 
24)  of  climbing speed  in  flies  treated  in  parallel  with  or  without  drug(s).  *indicates 
significant  difference  between  control  (NF)  and  treated  flies.  p values  (pair-wise 
Student’s t-test, two-tailed) are shown over asterisks. Note ameliorating effect of TEA on 
development of PTZ induced locomotor abnormality. See text for details.
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Figure 1
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Figure 2
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Figure 3
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Table 1. Enriched GO biological processes in genes upregulated by TEA.
GO_Term p-value
GO:0009628~response to abiotic stimulus 5.87E-07
GO:0007602~phototransduction 0.001
GO:0006412~translation 0.001
GO:0009314~response to radiation 0.001
GO:0030154~cell differentiation 0.003
GO:0046164~alcohol catabolic process 0.003
GO:0002165~instar larval or pupal development 0.004
GO:0018298~protein-chromophore linkage 0.004
GO:0009791~post-embryonic development 0.006
GO:0007610~behavior 0.007
GO:0000902~cell morphogenesis 0.008
GO:0007275~multicellular organismal development 0.008
GO:0008038~neuron recognition 0.01
GO:0008037~cell recognition 0.01
GO:0016198~axon choice point recognition 0.01
GO:0044275~cellular carbohydrate catabolic process 0.01
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GO:0007498~mesoderm development 0.01
GO:0006007~glucose catabolic process 0.01
GO:0046365~monosaccharide catabolic process 0.01
GO:0009084~glutamine family amino acid biosynthetic process 0.01
GO:0006006~glucose metabolic process 0.01
GO:0031667~response to nutrient levels 0.02
GO:0009653~anatomical structure morphogenesis 0.02
GO:0019318~hexose metabolic process 0.04
GO:0050877~neurological system process 0.04
GO:0048878~chemical homeostasis 0.04
GO:0009888~tissue development 0.04
p values  shown  are  after  Benjamini  adjustment.  Some  non-specific  or  overlapping 
processes are not presented.
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Table 2. Enriched pathways in genes upregulated by TEA.
Pathway p-value p-value
Unadjusted Benjamini
dme03010:Ribosome 5.38E-22 6.83E-20
dme00010:Glycolysis / Gluconeogenesis 0.029 0.84
dme00710:Carbon fixation 0.037 0.80
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Table S1. Genes up- and down-regulated in fly head after treatment of the 
animals with TEA for 7 d.
Upregulated Downregulated
Gene ID Gene symbol FlyBase ID Gene ID
Gene 
symbol FlyBase ID
CG10023 14-3-3zeta FBgn0000011 CG10869 CG10869 FBgn0000241
CG10037 7B2 FBgn0000024 CG11224 CG11224 FBgn0001313
CG10045 ARP-like FBgn0000038 CG11556 CG12567 FBgn0011288
CG10045 ATPsyn-beta FBgn0000047 CG11895 CG1344 FBgn0014022
CG10047 ATPsyn-d FBgn0000055 CG12567 CG13567 FBgn0024836
CG1007 AcCoAS FBgn0000056 CG1344 CG13872 FBgn0024989
CG10077 Ace FBgn0000063 CG13567 CG14096 FBgn0027507
CG10077 Act88F FBgn0000064 CG13872 CG14770 FBgn0028697
CG10081 Adam FBgn0000100 CG14096 CG15161 FBgn0029003
CG10106 Adh FBgn0000116 CG14770 CG17018 FBgn0029128
CG10108 Adhr FBgn0000120 CG15161 CG1750 FBgn0029573
CG10124 Akap200 FBgn0000150 CG17018 CG17613 FBgn0030081
CG10130 Ald FBgn0000163 CG17131 CG18217 FBgn0030230
CG10155 Aldh FBgn0000171 CG17420 CG2023 FBgn0031347
CG10161 Amph FBgn0000228 CG1750 CG30093 FBgn0032692
CG10197 Ance FBgn0000229 CG17613 CG31793 FBgn0034477
CG10214 Ank FBgn0000242 CG17632 CG33493 FBgn0034659
CG10226 Arf79F FBgn0000253 CG17866 CG3777 FBgn0034963
CG10233 Argk FBgn0000258 CG17884 CG40153 FBgn0036646
CG10253 Arr1 FBgn0000261 CG18217 CG4021 FBgn0036774
CG10293 Art4 FBgn0000283 CG2023 CG40327 FBgn0036871
CG10305 As FBgn0000287 CG30093 CG6463 FBgn0037383
CG10306 Asator FBgn0000307 CG31793 CG7246 FBgn0037600
CG10318 Atg8a FBgn0000308 CG3777 CG8007 FBgn0037749
CG10338 Atpalpha FBgn0000416 CG40153 CG9471 FBgn0039836
CG10346 Awh FBgn0000472 CG4021 CR32769 FBgn0039935
CG10375 BG4 FBgn0000479 CG40327 Nipped-A FBgn0039958
CG10377 Blimp-1 FBgn0000500 CG4746 Rlb1 FBgn0039972
CG10395 Bsg FBgn0000536 CG6463 RpL15 FBgn0040040
CG10406 Bsg25D FBgn0000556 CG7246 Rph FBgn0047038
CG10429 Bx FBgn0000557 CG7354 SP71 FBgn0050093
CG10433 CG10077 FBgn0000559 CG8007 Snap25 FBgn0051793
CG1049 CG10081 FBgn0000565 CG8161 kl-2 FBgn0053493
CG10539 CG10214 FBgn0000567 CG9471 mRpS26 FBgn0058153
CG10570 CG10226 FBgn0000575 CR32769 mab-2 FBgn0058327
CG10571 CG10233 FBgn0000592 GH25573 stan FBgn0062943
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CG10578 CG10253 FBgn0000635 LP05376
CG10590 CG10306 FBgn0000636 RE72566
CG10596 CG10338 FBgn0000711 SD04061
CG10645 CG10375 FBgn0001078
CG10652 CG10395 FBgn0001091
CG10658 CG10433 FBgn0001092
CG10680 CG10570 FBgn0001124
CG10698 CG10590 FBgn0001125
CG10710 CG10680 FBgn0001128
CG1072 CG10710 FBgn0001145
CG10743 CG10743 FBgn0001149
CG10746 CG10804 FBgn0001219
CG10757 CG10971 FBgn0001233
CG10798 CG10992 FBgn0001316
CG10798 CG11006 FBgn0001319
CG10804 CG11008 FBgn0001325
CG1081 CG1104 FBgn0001612
CG10810 CG11050 FBgn0001942
CG10811 CG11138 FBgn0001974
CG10833 CG11147 FBgn0002183
CG10837 CG11148 FBgn0002431
CG10842 CG11155 FBgn0002531
CG10846 CG11190 FBgn0002534
CG1088 CG11196 FBgn0002542
CG10888 CG11221 FBgn0002579
CG10944 CG11319 FBgn0002590
CG10971 CG11349 FBgn0002607
CG10977 CG11357 FBgn0002622
CG10988 CG11381 FBgn0002645
CG10992 CG11400 FBgn0002780
CG11006 CG11455 FBgn0002781
CG11008 CG11486 FBgn0002921
CG1104 CG11550 FBgn0002940
CG11050 CG11576 FBgn0002968
CG11062 CG11638 FBgn0003074
CG11064 CG11663 FBgn0003159
CG11064 CG11665 FBgn0003178
CG11081 CG11739 FBgn0003187
CG1112 CG11786 FBgn0003206
CG11138 CG11843 FBgn0003248
CG11138 CG11906 FBgn0003249
CG11147 CG11971 FBgn0003250
CG11147 CG12018 FBgn0003349
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CG11148 CG12025 FBgn0003357
CG11154 CG12121 FBgn0003360
CG11155 CG12128 FBgn0003375
CG11190 CG1213 FBgn0003380
CG11196 CG12184 FBgn0003392
CG11218 CG12204 FBgn0003396
CG11218 CG12214 FBgn0003447
CG11221 CG12267 FBgn0003464
CG11237 CG12289 FBgn0003498
CG11278 CG12488 FBgn0003567
CG11319 CG1249 FBgn0003607
CG11326 CG12543 FBgn0003715
CG11331 CG12660 FBgn0003721
CG11348 CG12730 FBgn0003738
CG11349 CG12802 FBgn0003744
CG11357 CG12822 FBgn0003748
CG11381 CG12900 FBgn0003866
CG11390 CG12991 FBgn0003943
CG11390 CG12992 FBgn0003961
CG11400 CG13078 FBgn0003995
CG11455 CG1311 FBgn0004034
CG11486 CG13116 FBgn0004110
CG11522 CG13126 FBgn0004227
CG11525 CG1315 FBgn0004237
CG11533 CG13154 FBgn0004242
CG11550 CG13248 FBgn0004362
CG11576 CG13295 FBgn0004366
CG11622 CG13565 FBgn0004369
CG11624 CG13737 FBgn0004404
CG11628 CG13779 FBgn0004413
CG11638 CG13784 FBgn0004432
CG11650 CG13830 FBgn0004456
CG11661 CG13868 FBgn0004551
CG11663 CG13895 FBgn0004595
CG11665 CG13907 FBgn0004607
CG1167 CG13995 FBgn0004620
CG1168 CG14017 FBgn0004623
CG11739 CG14040 FBgn0004624
CG11786 CG14096 FBgn0004625
CG11804 CG14109 FBgn0004629
CG11821 CG14207 FBgn0004657
CG11843 CG14277 FBgn0004828
CG11853 CG14292 FBgn0004838
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CG11886 CG14302 FBgn0004864
CG11906 CG14363 FBgn0004876
CG11949 CG1443 FBgn0004907
CG11958 CG14439 FBgn0004914
CG11971 CG14478 FBgn0004919
CG11981 CG14516 FBgn0004922
CG12018 CG14605 FBgn0005536
CG12025 CG14614 FBgn0005586
CG12052 CG1463 FBgn0005593
CG12055 CG14647 FBgn0005614
CG12055 CG14648 FBgn0005630
CG12070 CG14686 FBgn0005666
CG12121 CG14762 FBgn0005775
CG12128 CG14801 FBgn0005776
CG1213 CG14821 FBgn0008649
CG12131 CG14889 FBgn0010053
CG12143 CG14933 FBgn0010083
CG12176 CG14967 FBgn0010105
CG12184 CG14969 FBgn0010113
CG12204 CG14989 FBgn0010198
CG12214 CG15067 FBgn0010217
CG12233 CG15098 FBgn0010228
CG12267 CG15201 FBgn0010247
CG12289 CG15236 FBgn0010256
CG12297 CG15239 FBgn0010265
CG12311 CG15270 FBgn0010316
CG12317 CG15281 FBgn0010348
CG12324 CG15316 FBgn0010352
CG12348 CG15365 FBgn0010381
CG12358 CG1537 FBgn0010406
CG12373 CG15370 FBgn0010408
CG12399 CG15492 FBgn0010410
CG1242 CG15611 FBgn0010411
CG12488 CG15701 FBgn0010412
CG1249 CG15706 FBgn0010413
CG12543 CG15711 FBgn0010434
CG12591 CG15745 FBgn0010435
CG1263 CG15771 FBgn0010470
CG1263 CG15887 FBgn0010516
CG12660 CG15891 FBgn0010575
CG12730 CG15892 FBgn0010602
CG12740 CG15926 FBgn0010607
CG12740 CG1597 FBgn0010609
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CG12749 CG1600 FBgn0010638
CG12758 CG1607 FBgn0010704
CG12775 CG16705 FBgn0010768
CG12781 CG16719 FBgn0010772
CG12802 CG1674 FBgn0010905
CG12822 CG16789 FBgn0011217
CG12900 CG16798 FBgn0011219
CG12991 CG16799 FBgn0011244
CG12992 CG16817 FBgn0011259
CG13078 CG16926 FBgn0011272
CG1311 CG16936 FBgn0011280
CG13116 CG16941 FBgn0011296
CG13126 CG17018 FBgn0011455
CG13143 CG17041 FBgn0011576
CG1315 CG17065 FBgn0011584
CG13154 CG17100 FBgn0011592
CG13248 CG17121 FBgn0011642
CG13295 CG17124 FBgn0011648
CG13363 CG17168 FBgn0011656
CG13387 CG17273 FBgn0011695
CG13388 CG17278 FBgn0011712
CG13388 CG17280 FBgn0011747
CG13389 CG17454 FBgn0011760
CG1345 CG1746 FBgn0011823
CG13565 CG17508 FBgn0012034
CG13737 CG17528 FBgn0012036
CG1374 CG17715 FBgn0012037
CG13779 CG17724 FBgn0013272
CG13779 CG17766 FBgn0013305
CG13784 CG17883 FBgn0013325
CG13830 CG18170 FBgn0013334
CG1386 CG18292 FBgn0013467
CG13868 CG18445 FBgn0013718
CG13895 CG18549 FBgn0013725
CG13907 CG18591 FBgn0013751
CG1391 CG18646 FBgn0013763
CG13995 CG18745 FBgn0013984
CG14017 CG18778 FBgn0014000
CG14025 CG18810 FBgn0014009
CG14029 CG1970 FBgn0014010
CG14032 CG2016 FBgn0014019
CG14040 CG2082 FBgn0014023
CG14048 CG2083 FBgn0014026
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CG1406 CG2135 FBgn0014037
CG14080 CG2165 FBgn0014163
CG14096 CG2185 FBgn0014184
CG14109 CG2201 FBgn0014362
CG14162 CG2233 FBgn0014848
CG14206 CG2254 FBgn0014930
CG14207 CG2267 FBgn0015024
CG14277 CG2556 FBgn0015033
CG1429 CG2765 FBgn0015037
CG14292 CG2791 FBgn0015129
CG14302 CG2808 FBgn0015222
CG14363 CG2846 FBgn0015229
CG1443 CG2857 FBgn0015268
CG14437 CG2875 FBgn0015276
CG14439 CG2947 FBgn0015324
CG14478 CG2989 FBgn0015374
CG1449 CG30055 FBgn0015379
CG14516 CG3008 FBgn0015541
CG14605 CG30118 FBgn0015542
CG14614 CG3036 FBgn0015546
CG1463 CG30362 FBgn0015567
CG14647 CG30421 FBgn0015575
CG14648 CG30497 FBgn0015587
CG14686 CG3088 FBgn0015622
CG1475 CG31075 FBgn0015657
CG14762 CG31088 FBgn0015745
CG14801 CG31090 FBgn0015756
CG14821 CG31120 FBgn0015766
CG1483 CG31159 FBgn0015778
CG1488 CG31207 FBgn0015795
CG14889 CG31216 FBgn0015801
CG14904 CG31224 FBgn0015806
CG14933 CG3123 FBgn0015904
CG14938 CG31236 FBgn0015946
CG14948 CG31324 FBgn0015949
CG1495 CG3136 FBgn0016031
CG14967 CG31451 FBgn0016076
CG14969 CG31472 FBgn0016120
CG14989 CG31495 FBgn0016126
CG14991 CG3153 FBgn0016687
CG15015 CG31607 FBgn0016691
CG15067 CG31660 FBgn0016693
CG15098 CG31694 FBgn0016694
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CG15101 CG31705 FBgn0016700
CG15101 CG31778 FBgn0016701
CG15102 CG31781 FBgn0016724
CG1511 CG31814 FBgn0016930
CG15150 CG31846 FBgn0016977
CG15189 CG31886 FBgn0017397
CG15201 CG31974 FBgn0017418
CG15231 CG31997 FBgn0017545
CG15236 CG32029 FBgn0017549
CG15239 CG32082 FBgn0017558
CG1527 CG32100 FBgn0017565
CG15270 CG32103 FBgn0019664
CG15281 CG32105 FBgn0019940
CG15304 CG32137 FBgn0020240
CG15316 CG32159 FBgn0020257
CG15331 CG32245 FBgn0020299
CG15342 CG32295 FBgn0020303
CG15365 CG32343 FBgn0020309
CG1537 CG32406 FBgn0020440
CG15370 CG32432 FBgn0020445
CG15442 CG32479 FBgn0020496
CG1548 CG3252 FBgn0020497
CG15492 CG32645 FBgn0020513
CG15519 CG32654 FBgn0020611
CG15532 CG32709 FBgn0020618
CG15592 CG32744 FBgn0020623
CG1560 CG32803 FBgn0020660
CG1560 CG32810 FBgn0020767
CG15611 CG3287 FBgn0020907
CG15669 CG3305 FBgn0021818
CG15697 CG33080 FBgn0021872
CG15701 CG33303 FBgn0021906
CG15706 CG33523 FBgn0022029
CG15711 CG33785 FBgn0022073
CG15745 CG33786 FBgn0022097
CG15771 CG33791 FBgn0022238
CG1584 CG34118 FBgn0022347
CG15883 CG34119 FBgn0022960
CG15887 CG34139 FBgn0022985
CG15926 CG3523 FBgn0022987
CG1594 CG3556 FBgn0023077
CG1597 CG3597 FBgn0023129
CG1600 CG3604 FBgn0023170
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CG1607 CG3621 FBgn0023180
CG1629 CG3652 FBgn0023213
CG1630 CG3662 FBgn0023477
CG1634 CG3812 FBgn0023510
CG1651 CG3823 FBgn0024183
CG1668 CG3838 FBgn0024289
CG1668 CG3842 FBgn0024290
CG16705 CG3847 FBgn0024291
CG16719 CG3880 FBgn0024293
CG1674 CG3887 FBgn0024535
CG16740 CG3902 FBgn0024733
CG16747 CG3925 FBgn0024734
CG16747 CG3950 FBgn0024753
CG16757 CG3973 FBgn0024804
CG16757 CG3999 FBgn0024814
CG1676 CG40351 FBgn0024846
CG16778 CG4042 FBgn0024913
CG16789 CG4098 FBgn0024921
CG16798 CG4115 FBgn0024939
CG16799 CG4133 FBgn0024963
CG16817 CG4285 FBgn0024988
CG16901 CG4300 FBgn0024996
CG1691 CG4362 FBgn0025286
CG16916 CG4468 FBgn0025366
CG16926 CG4553 FBgn0025387
CG16936 CG4554 FBgn0025394
CG16941 CG4572 FBgn0025454
CG16944 CG4627 FBgn0025519
CG17018 CG4674 FBgn0025618
CG17018 CG4716 FBgn0025639
CG17023 CG4733 FBgn0025704
CG17035 CG4747 FBgn0025726
CG17041 CG4756 FBgn0025741
CG17046 CG4911 FBgn0025803
CG17051 CG4914 FBgn0025832
CG17065 CG5023 FBgn0025839
CG1710 CG5059 FBgn0025879
CG17100 CG5065 FBgn0025936
CG17121 CG5073 FBgn0026056
CG17124 CG5104 FBgn0026079
CG17124 CG5195 FBgn0026084
CG17142 CG5226 FBgn0026170
CG17143 CG5295 FBgn0026179
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CG17168 CG5315 FBgn0026199
CG17205 CG5343 FBgn0026268
CG17228 CG5362 FBgn0026320
CG17273 CG5382 FBgn0026370
CG17278 CG5431 FBgn0026371
CG17280 CG5468 FBgn0026380
CG17291 CG5493 FBgn0026409
CG17299 CG5500 FBgn0026439
CG17299 CG5522 FBgn0026533
CG17309 CG5543 FBgn0026565
CG17395 CG5597 FBgn0026577
CG17420 CG5629 FBgn0026578
CG1743 CG5651 FBgn0026708
CG17454 CG5674 FBgn0026741
CG1746 CG5708 FBgn0026869
CG1747 CG5778 FBgn0027095
CG17484 CG5793 FBgn0027291
CG17489 CG5815 FBgn0027348
CG17508 CG5830 FBgn0027356
CG17520 CG5867 FBgn0027378
CG17521 CG5872 FBgn0027493
CG17521 CG5919 FBgn0027525
CG17523 CG5958 FBgn0027534
CG17530 CG6084 FBgn0027571
CG17533 CG6091 FBgn0027574
CG17534 CG6095 FBgn0027586
CG17592 CG6115 FBgn0027590
CG17696 CG6133 FBgn0027595
CG1771 CG6145 FBgn0027608
CG17715 CG6163 FBgn0027619
CG1772 CG6179 FBgn0027654
CG17724 CG6180 FBgn0027784
CG17766 CG6287 FBgn0027796
CG17785 CG6329 FBgn0027903
CG17870 CG6357 FBgn0027932
CG17888 CG6409 FBgn0027945
CG17907 CG6426 FBgn0028400
CG17921 CG6486 FBgn0028425
CG1793 CG6579 FBgn0028433
CG1793 CG6656 FBgn0028490
CG1793 CG6696 FBgn0028536
CG17943 CG6707 FBgn0028540
CG17950 CG6762 FBgn0028562
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CG17964 CG6767 FBgn0028644
CG17975 CG6834 FBgn0028645
CG18001 CG6908 FBgn0028686
CG18026 CG6910 FBgn0028693
CG18069 CG6971 FBgn0028696
CG18090 CG6983 FBgn0028697
CG1810 CG7009 FBgn0028737
CG18102 CG7023 FBgn0028833
CG18108 CG7053 FBgn0028879
CG18111 CG7065 FBgn0028915
CG18176 CG7093 FBgn0028953
CG1821 CG7097 FBgn0028954
CG18279 CG7120 FBgn0028955
CG1828 CG7130 FBgn0028990
CG18285 CG7156 FBgn0029092
CG18292 CG7203 FBgn0029093
CG18314 CG7322 FBgn0029152
CG18314 CG7323 FBgn0029502
CG18345 CG7326 FBgn0029506
CG1838 CG7331 FBgn0029508
CG18402 CG7369 FBgn0029539
CG18405 CG7384 FBgn0029568
CG18445 CG7433 FBgn0029629
CG18485 CG7492 FBgn0029663
CG18497 CG7532 FBgn0029672
CG18531 CG7668 FBgn0029676
CG18549 CG7686 FBgn0029681
CG18578 CG7698 FBgn0029687
CG18591 CG7768 FBgn0029708
CG18646 CG7770 FBgn0029711
CG1865 CG7772 FBgn0029752
CG1873 CG7781 FBgn0029762
CG18741 CG7804 FBgn0029771
CG18745 CG7832 FBgn0029801
CG18778 CG7924 FBgn0029859
CG18810 CG7971 FBgn0029860
CG18817 CG8012 FBgn0029863
CG1883 CG8026 FBgn0029866
CG1901 CG8036 FBgn0029867
CG1970 CG8067 FBgn0029870
CG1970 CG8112 FBgn0029872
CG1981 CG8177 FBgn0029875
CG1982 CG8235 FBgn0029881
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CG2005 CG8249 FBgn0029897
CG2016 CG8273 FBgn0029898
CG2028 CG8312 FBgn0029990
CG2033 CG8317 FBgn0029994
CG2041 CG8329 FBgn0030035
CG2043 CG8343 FBgn0030069
CG2050 CG8379 FBgn0030077
CG2082 CG8446 FBgn0030091
CG2082 CG8538 FBgn0030107
CG2083 CG8602 FBgn0030109
CG2096 CG8636 FBgn0030133
CG2099 CG8677 FBgn0030136
CG2101 CG8738 FBgn0030159
CG2135 CG8778 FBgn0030160
CG2152 CG8788 FBgn0030171
CG2165 CG8863 FBgn0030235
CG2168 CG8873 FBgn0030260
CG2168 CG9008 FBgn0030269
CG2171 CG9056 FBgn0030272
CG2179 CG9140 FBgn0030289
CG2185 CG9238 FBgn0030300
CG2201 CG9253 FBgn0030332
CG2210 CG9306 FBgn0030367
CG2216 CG9328 FBgn0030396
CG2233 CG9336 FBgn0030400
CG2238 CG9339 FBgn0030406
CG2239 CG9360 FBgn0030421
CG2239 CG9396 FBgn0030444
CG2254 CG9399 FBgn0030469
CG2254 CG9445 FBgn0030471
CG2259 CG9448 FBgn0030506
CG2267 CG9498 FBgn0030521
CG2297 CG9510 FBgn0030556
CG2381 CG9515 FBgn0030600
CG2457 CG9603 FBgn0030608
CG2457 CG9663 FBgn0030702
CG2556 CG9689 FBgn0030723
CG2677 CG9691 FBgn0030740
CG2679 CG9770 FBgn0030742
CG2684 CG9777 FBgn0030764
CG2727 CG9813 FBgn0030788
CG2746 CG9836 FBgn0030846
CG2765 CG9894 FBgn0030847
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CG2791 CG9917 FBgn0030876
CG2808 CG9919 FBgn0030883
CG2827 CG9928 FBgn0030915
CG2830 COQ7 FBgn0030941
CG2841 CR30009 FBgn0030947
CG2846 CR30068 FBgn0030960
CG2857 CR31808 FBgn0030968
CG2875 CR32028 FBgn0030970
CG2922 CR32218 FBgn0030985
CG2928 Ca-P60A FBgn0031022
CG2947 CaMKI FBgn0031035
CG2958 CaMKII FBgn0031037
CG2989 Cam FBgn0031090
CG2998 Caps FBgn0031099
CG2999 Cat FBgn0031114
CG2999 Cct1 FBgn0031186
CG30011 Cdep FBgn0031228
CG30055 Ced-12 FBgn0031257
CG3008 Chit FBgn0031285
CG30118 Cip4 FBgn0031294
CG3018 CkIIalpha FBgn0031381
CG30295 CkIalpha FBgn0031417
CG3036 Clc FBgn0031453
CG30362 Cnx99A FBgn0031465
CG30421 Con FBgn0031516
CG30483 Cp190 FBgn0031556
CG30497 Csk FBgn0031562
CG3050 CtBP FBgn0031600
CG3088 CycG FBgn0031643
CG31075 Cyp1 FBgn0031645
CG31088 Cyp12a4 FBgn0031652
CG31090 Cyp12a5 FBgn0031670
CG31120 Cyp28d1 FBgn0031676
CG31159 Cyp304a1 FBgn0031689
CG31207 Cyp311a1 FBgn0031693
CG31209 Cyp313a1 FBgn0031721
CG31216 Cyp4ac1 FBgn0031734
CG31224 Cyp4d2 FBgn0031770
CG3123 Cyp4d21 FBgn0031771
CG31236 Cyp4d8 FBgn0031801
CG31324 Cyp4p1 FBgn0031814
CG3136 Cyp6d5 FBgn0031835
CG3136 Cyp6g1 FBgn0031836
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CG31361 Cyp6w1 FBgn0031850
CG3139 Cys FBgn0031855
CG3143 D2R FBgn0031897
CG31451 Dak1 FBgn0031913
CG31472 Dbp80 FBgn0031925
CG31495 Dek FBgn0031942
CG3153 DnaJ-1 FBgn0031962
CG31536 Doc3 FBgn0031965
CG31543 DopEcR FBgn0032008
CG31605 DopR2 FBgn0032021
CG31607 Dpit47 FBgn0032076
CG31660 Drs FBgn0032077
CG3169 Dsk FBgn0032079
CG31694 E23 FBgn0032123
CG31705 Eaat1 FBgn0032130
CG31719 Ect4 FBgn0032139
CG31764 Ef1alpha100E FBgn0032168
CG31764 Ef1alpha48D FBgn0032196
CG31778 Ef1beta FBgn0032237
CG31781 Ef2b FBgn0032248
CG31795 Eig71Eh FBgn0032262
CG31795 Eip71CD FBgn0032297
CG31814 Eip74EF FBgn0032350
CG31846 Eph FBgn0032409
CG3186 Est-6 FBgn0032422
CG31886 Fak56D FBgn0032453
CG3189 Fas2 FBgn0032472
CG31916 Fas3 FBgn0032482
CG31941 Fen1 FBgn0032511
CG3195 Fer1HCH FBgn0032518
CG31974 Fit1 FBgn0032640
CG31992 Fkbp13 FBgn0032656
CG31997 Flo-2 FBgn0032660
CG32018 Frq2 FBgn0032700
CG32019 GRHRII FBgn0032705
CG32019 GXIVsPLA2 FBgn0032809
CG3203 Gapdh1 FBgn0032836
CG32031 Gapdh2 FBgn0032849
CG32057 Gbeta76C FBgn0032856
CG32082 Gclc FBgn0032886
CG32100 Gfat2 FBgn0032897
CG32103 Ggamma30A FBgn0032901
CG32105 GluClalpha FBgn0032919
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CG32137 GluRIIA FBgn0032946
CG32156 Glycogenin FBgn0032949
CG32159 Golgin84 FBgn0032955
CG32180 Got1 FBgn0032960
CG32217 Got2 FBgn0032987
CG32245 Gp150 FBgn0032999
CG32316 Gpdh FBgn0033010
CG32316 Gr2a FBgn0033019
CG32343 Grip71 FBgn0033028
CG32380 Grp1 FBgn0033029
CG32381 Gs2 FBgn0033065
CG32406 GstD1 FBgn0033083
CG32423 GstE2 FBgn0033108
CG32423 GstE6 FBgn0033132
CG32432 GstE8 FBgn0033188
CG32434 GstE9 FBgn0033210
CG32479 Haspin FBgn0033229
CG32498 Hcf FBgn0033248
CG3252 Hex-t2 FBgn0033250
CG32592 His3.3B FBgn0033268
CG32593 HmgD FBgn0033321
CG32645 HmgZ FBgn0033327
CG32654 Hnf4 FBgn0033351
CG32672 Hph FBgn0033385
CG3269 Hrb27C FBgn0033391
CG32709 Hrb87F FBgn0033473
CG32744 Hsc70-4 FBgn0033476
CG32803 Hsp60B FBgn0033495
CG32810 Hsp83 FBgn0033515
CG32849 IM1 FBgn0033555
CG3287 IM10 FBgn0033736
CG32918 IM4 FBgn0033761
CG32954 IP3K2 FBgn0033772
CG33005 Imp FBgn0033802
CG33045 InR FBgn0033808
CG33048 Ip259 FBgn0033820
CG3305 Ipk1 FBgn0033822
CG33080 JhI-21 FBgn0033835
CG33085 Jheh1 FBgn0033853
CG33113 Jheh2 FBgn0033872
CG3314 Jon66Cii FBgn0033875
CG3315 Jon99Ciii FBgn0033891
CG3320 Kaz1-ORFA FBgn0033912
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CG3327 Kaz1-ORFB FBgn0033983
CG3340 Kr FBgn0034045
CG3360 Lag1 FBgn0034046
CG3395 Lcp1 FBgn0034089
CG3441 Lcp3 FBgn0034093
CG3466 Lig4 FBgn0034095
CG3523 Lsd-2 FBgn0034122
CG3525 MED19 FBgn0034140
CG3525 MED26 FBgn0034145
CG3556 MESK2 FBgn0034158
CG3572 MRG15 FBgn0034162
CG3576 Mad FBgn0034194
CG3597 Map205 FBgn0034198
CG3604 Mapmodulin FBgn0034249
CG3620 Marf FBgn0034282
CG3621 Mbs FBgn0034329
CG3652 Mcr FBgn0034331
CG3662 Mef2 FBgn0034355
CG3664 Mkp3 FBgn0034364
CG3665 Mkrn1 FBgn0034367
CG3682 Mocs1 FBgn0034398
CG3688 Mpcp FBgn0034405
CG3694 Msp-300 FBgn0034408
CG3705 Msr-110 FBgn0034421
CG3725 NC2alpha FBgn0034425
CG3747 NPC2 FBgn0034441
CG3747 Nacalpha FBgn0034452
CG3752 Nap1 FBgn0034470
CG3757 Nc73EF FBgn0034501
CG3798 Neb-cGP FBgn0034534
CG3811 Nedd4 FBgn0034538
CG3812 Nhe2 FBgn0034603
CG3823 Nmda1 FBgn0034638
CG3838 Nplp1 FBgn0034650
CG3842 Nrg FBgn0034654
CG3847 Nurf-38 FBgn0034734
CG3861 Oatp30B FBgn0034743
CG3869 Obp18a FBgn0034789
CG3880 Obp22a FBgn0034797
CG3887 Obp44a FBgn0034877
CG3902 Obp56d FBgn0034888
CG3925 Obp99a FBgn0034908
CG3950 Oda FBgn0034920
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CG3973 Orc6 FBgn0034935
CG3981 Os9 FBgn0034967
CG3989 Oscp FBgn0034968
CG3997 Oseg6 FBgn0035057
CG3999 Osi19 FBgn0035078
CG40049 Osi9 FBgn0035087
CG40080 PGRP-SC1b FBgn0035092
CG40283 PIP5K59B FBgn0035110
CG40289 PRL-1 FBgn0035113
CG40293 Paip2 FBgn0035158
CG4042 Pal FBgn0035173
CG4043 Parp FBgn0035239
CG4046 Past1 FBgn0035240
CG4059 Pbprp2 FBgn0035253
CG4098 Pcmt FBgn0035285
CG4115 Pdk FBgn0035374
CG4133 Pdp1 FBgn0035376
CG4157 PebIII FBgn0035397
CG4170 Pect FBgn0035420
CG4211 Pen FBgn0035422
CG4215 Pgi FBgn0035440
CG4233 Pomt2 FBgn0035495
CG4260 Pp2A-29B FBgn0035498
CG4264 Proct FBgn0035523
CG4264 Prosap FBgn0035533
CG4285 Prosbeta3 FBgn0035538
CG4300 Prp18 FBgn0035550
CG4307 Prx5037 FBgn0035558
CG4321 Ptp99A FBgn0035622
CG4345 PyK FBgn0035625
CG4347 Qm FBgn0035674
CG4362 RFeSP FBgn0035695
CG4392 RNaseX25 FBgn0035709
CG4396 Rab1 FBgn0035719
CG4396 Rab2 FBgn0035720
CG4429 Rab26 FBgn0035756
CG4443 Rab3 FBgn0035763
CG4464 Rab35 FBgn0035772
CG4468 Rab4 FBgn0035807
CG4494 Rab5 FBgn0035835
CG4501 Rab7 FBgn0035887
CG4533 Rack1 FBgn0035888
CG4550 Ranbp16 FBgn0035896
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CG4550 Ras64B FBgn0035922
CG4551 Rbp2 FBgn0035936
CG4553 Reg-5 FBgn0035946
CG4554 RfaBp FBgn0035954
CG4572 Rh2 FBgn0035959
CG4609 Rh3 FBgn0035978
CG4627 Rh4 FBgn0036015
CG4634 Rh5 FBgn0036022
CG4651 Rh6 FBgn0036029
CG4674 Rheb FBgn0036030
CG4716 RhoGAP54D FBgn0036038
CG4733 Ric FBgn0036043
CG4747 Rlc1 FBgn0036058
CG4756 Rlip FBgn0036106
CG4758 RluA-1 FBgn0036122
CG4759 RpL10Ab FBgn0036155
CG4798 RpL11 FBgn0036160
CG4799 RpL12 FBgn0036180
CG4800 RpL13 FBgn0036182
CG4807 RpL13A FBgn0036213
CG4816 RpL15 FBgn0036262
CG4838 RpL17 FBgn0036272
CG4881 RpL19 FBgn0036278
CG4897 RpL21 FBgn0036309
CG4898 RpL24 FBgn0036315
CG4911 RpL26 FBgn0036341
CG4914 RpL27 FBgn0036364
CG4921 RpL27A FBgn0036376
CG4944 RpL28 FBgn0036377
CG4979 RpL30 FBgn0036382
CG4993 RpL31 FBgn0036415
CG4993 RpL34b FBgn0036416
CG4994 RpL35A FBgn0036428
CG4999 RpL36 FBgn0036436
CG5014 RpL37A FBgn0036449
CG5014 RpL38 FBgn0036496
CG5023 RpL39 FBgn0036545
CG5055 RpL41 FBgn0036556
CG5059 RpL5 FBgn0036648
CG5065 RpL6 FBgn0036697
CG5073 RpL7 FBgn0036736
CG5093 RpL7A FBgn0036761
CG5094 RpL8 FBgn0036824
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CG5104 RpL9 FBgn0036825
CG5178 RpLP0 FBgn0036844
CG5184 RpS10b FBgn0036871
CG5185 RpS13 FBgn0036918
CG5192 RpS14b FBgn0036927
CG5195 RpS15Aa FBgn0036929
CG5210 RpS15Ab FBgn0036943
CG5216 RpS16 FBgn0036984
CG5226 RpS18 FBgn0036991
CG5232 RpS19a FBgn0036995
CG5249 RpS23 FBgn0037007
CG5277 RpS25 FBgn0037009
CG5279 RpS26 FBgn0037018
CG5295 RpS28b FBgn0037072
CG5315 RpS3 FBgn0037151
CG5330 RpS30 FBgn0037188
CG5333 RpS3A FBgn0037239
CG5336 RpS5a FBgn0037244
CG5341 RpS6 FBgn0037245
CG5343 RpS7 FBgn0037249
CG5352 RpS8 FBgn0037289
CG5358 RpS9 FBgn0037295
CG5362 Rpn12 FBgn0037302
CG5364 Rpt3 FBgn0037308
CG5382 Rrp46 FBgn0037328
CG5407 Rtnl1 FBgn0037346
CG5431 S6k FBgn0037351
CG5441 SAK FBgn0037358
CG5468 SF2 FBgn0037387
CG5472 SMSr FBgn0037416
CG5493 SNF4Agamma FBgn0037429
CG5500 SRPK FBgn0037434
CG5518 Sap-r FBgn0037467
CG5522 Sap47 FBgn0037486
CG5543 Sas FBgn0037533
CG5546 Scamp FBgn0037582
CG5547 Scp2 FBgn0037605
CG5557 Sec61beta FBgn0037607
CG5597 Sema-1a FBgn0037612
CG5629 Sgs5 FBgn0037637
CG5651 Sgt FBgn0037638
CG5659 Sh FBgn0037686
CG5670 Sh3beta FBgn0037712
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CG5674 Sir2 FBgn0037714
CG5674 Sk1 FBgn0037715
CG5680 Slbp FBgn0037716
CG5708 Slob FBgn0037720
CG5711 SmB FBgn0037728
CG5711 Snap FBgn0037734
CG5738 Sodh-1 FBgn0037767
CG5778 Spn FBgn0037770
CG5784 Spn27A FBgn0037780
CG5793 Spn43Ab FBgn0037801
CG5803 Spred FBgn0037813
CG5813 Spt3 FBgn0037815
CG5815 Stim FBgn0037832
CG5820 Stlk FBgn0037856
CG5821 Su(Tpl) FBgn0037874
CG5826 Su(var)205 FBgn0037925
CG5827 Sur-8 FBgn0037935
CG5827 Suv4-20 FBgn0037936
CG5830 Syt7 FBgn0037962
CG5867 SytIV FBgn0037981
CG5872 Syx13 FBgn0038017
CG5887 Tal FBgn0038045
CG5887 Tctp FBgn0038053
CG5907 Thd1 FBgn0038055
CG5915 Thor FBgn0038057
CG5919 Timp FBgn0038095
CG5935 Tkr FBgn0038100
CG5958 Tm1 FBgn0038132
CG6011 Tom FBgn0038143
CG6027 Tpi FBgn0038145
CG6030 Treh FBgn0038185
CG6030 Trn FBgn0038194
CG6042 Trp1 FBgn0038197
CG6058 TrxT FBgn0038198
CG6084 Tsp FBgn0038223
CG6091 Tsp42Ea FBgn0038236
CG6092 Tsp42Ee FBgn0038257
CG6095 Tsp42Ej FBgn0038310
CG6115 Tsp66E FBgn0038331
CG6133 U2A FBgn0038398
CG6141 UGP FBgn0038426
CG6145 Ubi-p63E FBgn0038443
CG6148 Ugt86Da FBgn0038464
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CG6163 Unc-76 FBgn0038474
CG6179 Uro FBgn0038504
CG6180 Usf FBgn0038519
CG6190 Vap-33-1 FBgn0038588
CG6281 Vha26 FBgn0038636
CG6287 Vha36 FBgn0038647
CG6329 Vha44 FBgn0038658
CG6341 Vps32 FBgn0038680
CG6357 Xbp1 FBgn0038681
CG6357 Xe7 FBgn0038738
CG6363 Zyx102EF FBgn0038744
CG6384 aay FBgn0038749
CG6409 ab FBgn0038774
CG6426 activin-beta FBgn0038784
CG6433 ade5 FBgn0038834
CG6469 alan-shepard FBgn0038858
CG6477 ald FBgn0038861
CG6486 alpha-Adaptin FBgn0038876
CG6500 alpha-Est7 FBgn0038912
CG6531 antdh FBgn0038928
CG6556 ara FBgn0038930
CG6571 ari-1 FBgn0038950
CG6575 atl FBgn0038984
CG6579 awd FBgn0039025
CG6625 baggins FBgn0039043
CG6656 baz FBgn0039054
CG6668 beat-Ib FBgn0039102
CG6684 beat-Ic FBgn0039115
CG6696 bel FBgn0039116
CG6707 bgm FBgn0039188
CG6730 bsk FBgn0039213
CG6762 bt FBgn0039264
CG6767 cactin FBgn0039269
CG6772 cathD FBgn0039298
CG6779 cdi FBgn0039336
CG6834 ced-6 FBgn0039359
CG6834 chic FBgn0039401
CG6846 chif FBgn0039434
CG6871 cib FBgn0039461
CG6889 cnk FBgn0039580
CG6908 comm FBgn0039620
CG6910 cora FBgn0039630
CG6917 crl FBgn0039640
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CG6948 crol FBgn0039678
CG6971 ctp FBgn0039713
CG6983 dap FBgn0039757
CG6987 defl FBgn0039792
CG6992 dei FBgn0039830
CG6998 desat1 FBgn0039844
CG7009 dm FBgn0039857
CG7013 dnc FBgn0039858
CG7023 dod FBgn0039864
CG7053 dpr10 FBgn0039874
CG7065 dpr16 FBgn0039882
CG7070 dpr17 FBgn0039896
CG7085 dpr18 FBgn0039897
CG7093 dpr6 FBgn0039900
CG7097 dre4 FBgn0039904
CG7105 dyn-p25 FBgn0039907
CG7111 eIF-3p66 FBgn0039908
CG7120 eIF-4B FBgn0039909
CG7130 eIF-4G FBgn0039914
CG7156 eIF-4a FBgn0039923
CG7156 eIF-5A FBgn0039927
CG7170 eIF2B-beta FBgn0039936
CG7171 eIF3-S10 FBgn0039943
CG7184 eIF4E-4 FBgn0039970
CG7186 eas FBgn0039972
CG7203 eff FBgn0039977
CG7241 elfless FBgn0040005
CG7266 emb FBgn0040007
CG7283 emc FBgn0040022
CG7291 emp FBgn0040071
CG7322 exba FBgn0040102
CG7323 fax FBgn0040222
CG7326 fdl FBgn0040227
CG7331 fidipidine FBgn0040228
CG7361 flw FBgn0040259
CG7369 fne FBgn0040284
CG7384 fok FBgn0040285
CG7390 foxo FBgn0040297
CG7393 fra FBgn0040319
CG7398 ftz-f1 FBgn0040351
CG7425 gem FBgn0040389
CG7433 glec FBgn0040395
CG7437 gol FBgn0040502
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CG7490 grim FBgn0040529
CG7492 gw FBgn0040653
CG7503 hdc FBgn0040674
CG7532 hiw FBgn0040732
CG7532 hop FBgn0040752
CG7535 how FBgn0040823
CG7555 hrg FBgn0040832
CG7576 hyd FBgn0040918
CG7583 ia2 FBgn0040954
CG7583 igl FBgn0040968
CG7586 inaF FBgn0040970
CG7590 jdp FBgn0040985
CG7594 klar FBgn0040992
CG7596 kn FBgn0041004
CG7605 l(1)G0030 FBgn0041094
CG7622 l(1)G0156 FBgn0041109
CG7643 l(1)dd4 FBgn0041111
CG7644 l(2)05714 FBgn0041186
CG7662 l(2)35Bd FBgn0041191
CG7668 l(2)44DEa FBgn0041342
CG7686 l(2)NC136 FBgn0041707
CG7698 l(2)efl FBgn0041723
CG7725 l(2)k01209 FBgn0042102
CG7726 l(2)s5379 FBgn0042119
CG7734 l(3)L1231 FBgn0042133
CG7758 l(3)neo18 FBgn0042710
CG7768 lama FBgn0043044
CG7770 lds FBgn0043070
CG7772 lectin-24Db FBgn0043456
CG7773 lgs FBgn0043539
CG7781 lilli FBgn0043841
CG7781 lola FBgn0044510
CG7804 lolal FBgn0045038
CG7808 lwr FBgn0045063
CG7832
mRNA-capping-
enzyme FBgn0045073
CG7836 mRpL14 FBgn0046692
CG7836 mRpL18 FBgn0046706
CG7867 mRpL27 FBgn0046763
CG7867 mRpS11 FBgn0047303
CG7895 mRpS18B FBgn0050009
CG7905 mRpS33 FBgn0050011
CG7924 mRpS35 FBgn0050055
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CG7951 mRpS5 FBgn0050118
CG7971 maf-S FBgn0050295
CG8012 mav FBgn0050362
CG8026 mew FBgn0050421
CG8036 mmd FBgn0050497
CG8037 mod FBgn0051075
CG8048 mod(mdg4) FBgn0051088
CG8048 mub FBgn0051090
CG8050 myoglianin FBgn0051120
CG8050 mys FBgn0051159
CG8055 nAcRbeta-64B FBgn0051207
CG8067 nahoda FBgn0051216
CG8112 ninaE FBgn0051224
CG8174 nonA FBgn0051236
CG8177 norpA FBgn0051324
CG8186 nrv3 FBgn0051361
CG8194 nuf FBgn0051451
CG8235 p120ctn FBgn0051472
CG8249 p38b FBgn0051495
CG8251 pan FBgn0051536
CG8253 phyl FBgn0051607
CG8273 pix FBgn0051660
CG8280 plexA FBgn0051694
CG8280 ppa FBgn0051719
CG8312 ppl FBgn0051778
CG8317 pros FBgn0051781
CG8329 ptr FBgn0051814
CG8343 pyx FBgn0051846
CG8345 qkr54B FBgn0051974
CG8379 qkr58E-2 FBgn0051992
CG8385 qua FBgn0051997
CG8409 rdgC FBgn0052029
CG8415 retm FBgn0052057
CG8418 rho-5 FBgn0052082
CG8426 rin FBgn0052100
CG8430 rogdi FBgn0052103
CG8446 salr FBgn0052105
CG8453 sano FBgn0052137
CG8453 sbb FBgn0052159
CG8472 scyl FBgn0052218
CG8538 sda FBgn0052245
CG8573 sdt FBgn0052295
CG8577 sec6 FBgn0052343
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CG8581 sesB FBgn0052380
CG8582 shi FBgn0052406
CG8602 shn FBgn0052423
CG8604 sima FBgn0052432
CG8636 siz FBgn0052479
CG8637 smi35A FBgn0052645
CG8648 smp-30 FBgn0052654
CG8663 smt3 FBgn0052672
CG8672 sn FBgn0052709
CG8677 sol FBgn0052744
CG8732 spel1 FBgn0052803
CG8732 spen FBgn0053002
CG8738 sqd FBgn0053080
CG8759 sqz FBgn0053113
CG8770 stumps FBgn0053180
CG8778 su(Hw) FBgn0053303
CG8788 sut2 FBgn0053517
CG8808 sxe2 FBgn0053523
CG8817 syt FBgn0053653
CG8824 tara FBgn0053715
CG8827 thoc7 FBgn0061361
CG8846 tin FBgn0061362
CG8863 to FBgn0061469
CG8873 trc FBgn0062447
CG8884 trpl FBgn0062463
CG8886 trus FBgn0062978
CG8893 tsh FBgn0063440
CG8900 tun FBgn0063491
CG8922 unc-13 FBgn0063492
CG8989 unc-13-4A FBgn0063494
CG8996 veli FBgn0063498
CG9008 vig FBgn0063923
CG9042 vimar FBgn0063924
CG9056 vir-1 FBgn0064145
CG9057 vri FBgn0064225
CG9075 vvl FBgn0066084
CG9075 wal FBgn0083167
CG9126 wgn FBgn0083228
CG9140 y FBgn0083954
CG9163 yellow-h FBgn0083955
CG9195 zfh2 FBgn0083975
CG9238
CG9238
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CG9253
CG9256
CG9282
CG9306
CG9310
CG9328
CG9336
CG9339
CG9354
CG9354
CG9360
CG9360 
CG9364
CG9378
CG9390
CG9396
CG9399
CG9399
CG9412
CG9415
CG9445
CG9448
CG9480
CG9484
CG9498
CG9528
CG9553
CG9553
CG9569
CG9575
CG9603
CG9663
CG9668
CG9689
CG9691
CG9748
CG9762
CG9770
CG9777
CG9805
CG9813
CG9836
CG9847
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CG9854
CG9894
CG9894
CG9916
CG9917
CG9919
CG9928
CG9928
CG9952
CG9954
CR30009
CR30068
CR30425
CR31808
CR32028
GH13704
GM03661
GM03914
GM04363
GM04742
GM06790
GM08821
HL01242
HL03474
LD01252
LD02060
LD10161
LD11083
LD12893
LD12894
Gene and FlyBase IDs are in ascending order, and gene symbol in alphabetical order
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